FDA OKs Zanubrutinib (Brukinsa) for CLL or SLL FDA OKs Zanubrutinib (Brukinsa) for CLL or SLL
The FDA granted accelerated approval to the BTK inhibitor zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Greenlights BTK Inhibitor Zanubrutinib for CLL/SLL
(MedPage Today) -- The FDA has approved the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Approval was based on results... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 20, 2023 Category: American Health Source Type: news
Brukinsa (zanubrutinib) Approved in the U.S. for Chronic Lymphocytic Leukemia
BASEL, Switzerland& BEIJING& CAMBRIDGE, Mass. -- January 19, 2023 --(BUSINESS WIRE)-- BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 19, 2023 Category: Drugs & Pharmacology Source Type: news
FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa, BeiGene USA, Inc.) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Chronic Lymphocytic Leukemia Highlights From ASH 2022 Chronic Lymphocytic Leukemia Highlights From ASH 2022
Dr Jan Burger reports on key data in chronic lymphocytic leukemia from ASH 2022, focusing on treatment-free remission, triple combination therapy, and BTK inhibitors pirtobrutinib and zanubrutinib.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2023 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news
Progression-Free Survival Increased With Zanubrutinib in Leukemia
TUESDAY, Jan. 3, 2023 -- Progression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2023 Category: Pharmaceuticals Source Type: news
Cell treatment that 'resets' immune system gives 250,000 British blood cancer patients new hope
Robin Edwards (pictured), 66, from Derbyshire, the first UK chronic lymphocytic leukaemia patient to receive the treatment has revealed he is now free of the disease after just two infusions. (Source: the Mail online | Health)
Source: the Mail online | Health - December 31, 2022 Category: Consumer Health News Source Type: news
Mayo Clinic Q & amp;A podcast: Advancing treatments for acute myeloid leukemia
Acute myeloid leukemia (AML), also called acute myelogenous leukemia, is a cancer of the blood and bone marrow, the spongy tissue inside bones where blood cells are made. The disease progresses rapidly, affecting a group of white blood cells called myeloid cells, which normally develop into mature red blood cells, white blood cells and platelets. "There are acute and chronic leukemias, explains Dr. James Foran, an oncologist at Mayo Clinic. "The chronic ones tend to happen… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 20, 2022 Category: Databases & Libraries Source Type: news
CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib
The second-generation Bruton ' s tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study in patients with chronic lymphocytic leukemia (CLL) .MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Adherence to Quality Indicators Low in Chronic Myeloid Leukemia
Compliance with diagnostic and therapeutic indicators was 83 and 78 percent, while compliance with monitoring indicators was lower (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 23, 2022 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news
Adherence to Quality Indicators Low in Chronic Myeloid Leukemia
WEDNESDAY, Nov. 23, 2022 -- For newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients, adherence to guideline-based quality indicators is low, according to a study published online Nov. 11 in Leukemia& Lymphoma.
Genevi ève... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2022 Category: Pharmaceuticals Source Type: news
